Core Viewpoint - Getein Biotech, Inc. reported a decline in revenue and net profit for the first half of 2025, with a focus on maintaining a strong position in the in vitro diagnostics (IVD) market despite challenges [1][2]. Financial Performance - Revenue for the first half of 2025 was approximately RMB 512.69 million, a decrease of 17% compared to RMB 617.67 million in the same period last year [2]. - Total profit for the period was RMB 110.53 million, down 33.49% from RMB 166.18 million year-on-year [2]. - Net profit attributable to shareholders was RMB 108.81 million, reflecting a 25.88% decline from RMB 146.81 million in the previous year [2]. - The company proposed a cash dividend of RMB 0.9 per 10 shares, amounting to a total distribution of approximately RMB 45.64 million, which represents 41.95% of the net profit for the period [1]. Industry Overview - The global IVD market is projected to reach USD 109.2 billion in 2024 and is expected to grow significantly, driven by factors such as policy support, aging populations, and rising chronic disease rates [4][5]. - In China, the IVD market has experienced rapid growth due to increased healthcare demand, improved medical insurance coverage, and advancements in domestic technology [5][6]. - The POCT segment is one of the fastest-growing areas in the IVD market, driven by the convenience and speed of testing, with significant potential for future growth [6]. Company Strategy and Product Development - The company has established eight major technology platforms, including POCT, chemiluminescence, biochemical detection, and molecular detection, to meet clinical needs [7][9]. - Getein has transitioned from a single POCT product line to a diverse range of products, including high-throughput and automated solutions for various healthcare settings [9][10]. - The company is actively expanding its market presence both domestically and internationally, with a focus on building a robust sales network through partnerships with over 3,000 distributors [12][13]. Regulatory and Market Position - As of June 30, 2025, the company held a total of 3,245 product registration certificates, with 460 of these being domestic [11][12]. - Getein's products are now available in 67 countries and regions, with a total of 2,785 product import licenses obtained [12][11]. - The company is committed to maintaining high-quality standards in production, adhering to ISO13485 quality management systems, and ensuring compliance with medical device regulations [14][15].

Core Viewpoint - The report highlights the financial performance and operational developments of Getein Biotech, indicating a decrease in revenue and profit while emphasizing ongoing innovation and market expansion efforts [1][2][3]. Financial Performance - Total assets at the end of the reporting period reached approximately CNY 3.91 billion, an increase of 5.47% compared to the previous year [3]. - Operating revenue for the first half of 2025 was approximately CNY 512.69 million, representing a decrease of 17.00% year-on-year [3]. - Total profit amounted to approximately CNY 110.53 million, down 33.49% from the previous year [3]. - Net profit attributable to shareholders was approximately CNY 93.23 million, a decrease of 28.52% year-on-year [3]. - The cash dividend proposed is CNY 0.9 per 10 shares, accounting for 41.95% of the net profit for the first half of 2025 [2]. Business Operations - The company continues to focus on its core business, with the chemical luminescence segment generating revenue of approximately CNY 150 million, a year-on-year increase of 10.64% [7]. - The company has developed 104 chemical luminescence detection projects, achieving full coverage of common clinical diseases [7]. - The Metis600 and Metis7000 automated biochemical immunoassay lines have been upgraded to enhance efficiency and adaptability for clinical needs [8][9]. - The GN7000/GN7120 automatic nucleic acid amplification analyzers have been launched, achieving significant market penetration with nearly 60 units installed since December 2024 [10]. Innovation and R&D - The company holds a total of 383 patents, including 57 invention patents, indicating a strong focus on innovation [11]. - The introduction of self-developed raw materials has increased the self-sufficiency rate of key materials to over 90% [13]. - The company is committed to expanding its product line and enhancing the performance of existing products to reduce production costs [13]. International Expansion - The company has established product entry permits in 67 countries, with nearly 2800 products approved for import [14]. - The international marketing strategy includes both online and offline channels, enhancing brand recognition and market share [14]. - The company has participated in exhibitions in Dubai and Nigeria, further promoting its global presence [14]. Quality Management - The company adheres to strict quality management standards, aligning with international regulations and certifications [15]. - A comprehensive quality management system has been established, covering all stages from R&D to delivery [15]. - The company has conducted multiple training sessions to enhance the skills of its service team, ensuring high customer satisfaction [16].

证券代码：603387 证券简称：基蛋生物 公告编号：2025-031 ? 每股分配比例：向全体股东每10股派发人民币0.9元（含税）。 ? 本次利润分配以实施权益分派股权登记日总股本数为基数，具体日期将 在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生变 动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整情 况。 一、利润分配方案内容 截至 2025 年 6 月 30 日，公司合并报表归属于上市公司股东的净利润为人民 币 108,808,763.23 元 ， 母 公 司 报 表 中 期 末 未 分 配 利 润 为 人 民 币 每 10 股派发人民币 0.9 元（含税），以第四届董事会第七次会议召开日的前一个 交易日（即 2025 年 8 月 28 日）总股本 507,153,517 股进行计算，公司共需派发 现金股利 45,643,816.53 元。此次现金分红占 2025 年半年度合并报表归属于上 市公司股东的净利润比例为 41.95%。 如在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额 不变，相应调整每股分配比例，并将另行公告具体调整情况。 根据公 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-030 基蛋生物科技股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届监事会第七次会议的通知 已于2025年8月18日以电子邮件的方式发出，通知了全体监事和其他列席人员。公司本 次监事会会议于2025年8月29日以现场及通讯表决方式召开。会议应出席监事3人，实际 出席监事3人。会议由监事会主席李靖召集和主持，公司董事会秘书和财务负责人列席 了本次监事会会议。本次会议的召开符合《中华人民共和国公司法》和《基蛋生物科技 股份有限公司章程》及有关法律法规的规定，会议决议合法有效。 二、监事会会议审议情况 （一）审议并通过《关于公司〈2025年半年度报告〉及其摘要的议案》 公司根据2025年半年度的实际经营情况和财务状况，依照有关规定编制《2025年半 年度报告》及其摘要。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)及《上 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-029 基蛋生物科技股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届董事会第七次会议的通知 已于 2025 年 8 月 18 日以电子邮件形式向全体董事发出。本次会议于 2025 年 8 月 29 日 以现场及通讯表决方式召开。会议应出席董事 9 人，实际出席董事 9 人。本次会议由董 事长苏恩本先生主持，公司全体监事和高级管理人员列席了本次会议。本次会议的召开 符合《中华人民共和国公司法》和《基蛋生物科技股份有限公司章程》及有关法律法规 的规定，会议决议合法有效。 二、董事会会议审议情况 （一）审议并通过《关于公司〈2025 年半年度报告〉及其摘要的议案》 公司根据 2025 年半年度的实际经营情况和财务状况，依照有关规定编制《2025 年 半年度报告》及其摘要。董事会审核后认为公司编制的 2025 年半年度报告及其摘要， 可以全面、客观、 ...

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 15, 2025, at 14:00 [1] - The meeting will take place at the fourth-floor conference room of the company located at No. 9, Bofu Road, Yangtze River Industrial Development Zone, Liuhe District, Nanjing [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Specific voting times include trading hours: 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [4] Shareholder Participation - Only shareholders registered by the close of trading on September 8, 2025, are eligible to attend the meeting [6] - Shareholders can appoint proxies to attend and vote on their behalf, with specific documentation required for both representatives and proxies [5][6] Notification Services - The company will utilize a reminder service provided by Shanghai Stock Exchange Information Network Co., Ltd. to notify shareholders about the meeting and voting [3][4] - Notifications will be sent via smart SMS to ensure that small and medium investors can participate [3]

Group 1 - The company held its fourth board meeting on August 29, 2025, where it approved the proposal to revise and establish corporate governance-related systems [1] - The revisions and new systems are aimed at standardizing company operations in accordance with the Company Law and Securities Law of the People's Republic of China, as well as the revised Articles of Association [1] - The proposed systems will be submitted for shareholder meeting approval, with the first seven items requiring such approval [1][2] Group 2 - The company has disclosed the details of the revised and newly established governance systems on the Shanghai Stock Exchange website and in the Shanghai Securities Journal [1]

一、资产减值准备的计提概况 证券代码：603387 证券简称：基蛋生物 公告编号：2025-035 基蛋生物科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为客观、公允、准确地反映基蛋生物科技股份有限公司（以下简称"公司"） 截至 2025 年 6 月 30 日的资产状况和 2025 年半年度的经营成果，根据《企业会 计准则》和公司会计政策相关规定，基于谨慎性原则，公司对截至 2025 年 6 月 将相关情况公告如下： 项目 确定组合的依据 本公司对单项金额在初始确认后已经发生信用减值的应收账款、其他应收款 单独确定其信用损失。 为客观、公允、准确地反映公司财务状况和经营成果，根据《企业会计准则》 和公司相关会计政策的相关规定，基于谨慎性原则，公司对截至 2025 年 6 月 30 日的各项资产进行了减值迹象的识别和测试，并根据识别和测试的结果，计提了 相关资产的减值准备。公司 2025 年 1-6 月对各项资产计提减值准备合计为 当在单项工具层面无法以合理成本 ...

Core Viewpoint - The company is actively implementing the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance corporate governance, innovation capabilities, and investor communication while ensuring sustainable returns for investors [1][6]. Group 1: Focus on IVD Main Business and Operational Quality - The company aims to become a globally competitive biotechnology firm by focusing on the IVD sector, expanding its product lines from low-throughput to high-throughput and automated systems, covering various testing fields [1]. - The company has established eight technology platforms and has expanded its overseas market presence to 130 countries, with overseas product revenue reaching 0.73 billion, a year-on-year increase of 45.42% [1]. - The revenue from the chemical luminescence product line reached 1.50 billion, a year-on-year increase of 10.64%, accounting for 33.54% of the company's self-produced product revenue [1]. Group 2: Increased R&D Investment and Innovation Capability - The company has increased its R&D investment to 0.88 billion in the first half of 2025, representing 17.24% of its operating income, focusing on developing differentiated products based on clinical needs [2]. - As of June 30, 2025, the company holds 383 effective patents, including 57 invention patents, 296 utility model patents, and 30 design patents [2]. - The company follows a "produce one generation, research one generation, reserve one generation" strategy to enhance its R&D capabilities and product innovation [2]. Group 3: Enhanced Corporate Governance and Compliance - The company is revising its governance structure by abolishing the supervisory board and transferring its responsibilities to the audit committee, pending approval at the 2025 first extraordinary general meeting [3]. - The company emphasizes the importance of internal control effectiveness and regularly evaluates its governance structure to ensure compliance with laws and regulations [4][5]. Group 4: Strengthened Investor Communication - The company is committed to transparent information disclosure and actively engages with investors through various channels, including performance briefings and visual reports on its official platforms [4]. - The company has established a dedicated investor relations email and hotline to facilitate ongoing communication with investors [4]. Group 5: Continuous Cash Dividends and Investor Return Mechanism - The company completed a cash dividend distribution of 0.9 yuan per 10 shares on June 17, 2025, totaling approximately 45.64 million, with cumulative cash dividends and buybacks exceeding 8.51 billion since its IPO [5]. - The company plans to maintain a stable cash dividend strategy and develop reasonable profit distribution plans to reward investors [5]. Group 6: Ongoing Evaluation of Action Plan - The company will continue to advance and assess the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan while fulfilling its information disclosure obligations [6].

Group 1 - The company plans to abolish the supervisory board and amend its Articles of Association to enhance governance structure and operational standards [1][2] - The supervisory functions will be transferred to the audit committee under the board of directors, in compliance with relevant laws and regulations [1][2] - The proposal to abolish the supervisory board will be submitted for approval at the shareholders' meeting [1] Group 2 - The company will revise the relevant clauses in its Articles of Association, including the definition of stakeholders to include employees [2][3] - The company is registered in Nanjing and operates under the unified social credit code [3][4] - The Articles of Association will serve as a legally binding document governing the rights and obligations between the company, shareholders, and management [6][11] Group 3 - The company’s business scope includes various technical services, medical device production, and sales [7][8] - The company’s shares are to be issued based on principles of fairness and equality, ensuring equal rights for all shareholders [17][18] - The company has specific provisions regarding the acquisition of its own shares, which require shareholder approval under certain conditions [24][25]